Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Visit the company website

 

Bullboard - Investor Discussion Forum Voyageur Pharmaceuticals Ltd V.VM

Alternate Symbol(s):  VYYRF

Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine Active Pharmaceutical Ingredients (API) and offers high-performance imaging contrast agents. The Company is focused on vertically integrating the barium and iodine contrast market, and aims at producing its own barium, iodine, and endo fullerenes. The Company’s products include SmoothX... see more

TSXV:VM - Post Discussion

View:
Post by WarrantOfficer on May 29, 2024 8:24am

PR vs Website

Voyageur website states Vision HD 98%, Vision LD 96%, SmoothHD 105%, SmoothLD 60% can also be ordered. Yesterdays PR states that these 4 products are in their late stages of development......confusion....  If an entity wants to order the remaining four products, they are put on hold as the final development is not complete? IMO, not a good start to building a customer base, let alone a trusting relationship with perspective customers. I know it seems I am always picking fly pooh out of pepper, but...........

The PR does not state when the the first three years of commercialization should / could begin. There could be years of regulatory approval, as no guidance was shared. 

I'm throwing darts here but is this supposed to make everyone happy before the annual AGM in June?

On a positive note, this company does offer the sky as potential. Thats why I am here.
Comment by Farmer9 on May 29, 2024 10:01am
Excellent points and a very balanced look at VM.  Can't disagree with anything you said.  I'm here for the potential as well!
Comment by postie1 on May 29, 2024 7:42pm
Here is the news release that is posted on VMs site..(imo) If this is correct then there is a chance that there was some editing done to the news release news-SmoothX-Contract-May-2024-1.pdf (voyageurpharmaceuticals.ca)
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.VM

follow v.vm on


Voyageur Pharmaceuticals Deck 2024..

The Watchlist

Voyageur Pharmaceuticals | The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

COMPELLING
VALUE PROPOSITION

  • Only pharmaceutical company in the world that owns long-term supply of barium and iodine
  • Natural barium and iodine resources meet increasingly limited global supply and risk
  • Multi-billion-dollar global market for contrast media
  • Poised to obtain significant market share by offering high-quality, lower-cost products
  • Favorable regulatory pathway allows rapid commercialization
  • Highly experienced team has positioned the company for profitable commercial success

Contact Us

Brent Willis, CEO
Brent@Vpharma.ca

Address:
Suite 1600 Dome Tower, 333 7th Avenue S.W.
Calgary, Alberta
T2P 2Z1